Aera Technology Releases New Capabilities to Accelerate Decision Intelligence Adoption
6.6.2022 20:00:00 EEST | Business Wire | Press release
Gartner Supply Chain Symposium/Xpo™ 2022 — Aera Technology today announced from the Gartner® Supply Chain Symposium/Xpo™ 2022, the release of new AI/MLOps and developer capabilities for its Aera Decision Cloud™ platform. To speed and scale decision automation, these enhancements add to the platform’s data science engine and provide advanced features for understanding the relationships and effectiveness of decisions. The innovations also strengthen Aera Decision Cloud’s capabilities for supply chain decision flows.
Aera Decision Cloud is designed to accelerate the adoption of Decision Intelligence — the digitization, augmentation, and automation of decision making. It enables companies to make and execute decisions in real-time to optimize business, financial, and operational performance.
According to Gartner, “by 2025, 95% of decisions that currently use data will be at least partially automated.”* Implementing and scaling automated decision-making across one or multiple business functions is difficult and time-consuming without a purpose-built platform. Aera Decision Cloud was designed from the start to empower users with the advanced technologies and tools, in one platform, to aggregate and integrate data from internal and external systems and sources and build and deploy decision-making models that generate informed, automated recommendations for any business scenario.
Today’s product release provides new features for business users that advance and scale Aera Cognitive Skills™ — the platform’s pre-built set of comprehensive decision-making capabilities for demand forecasting, planning, inventory, logistics, procurement, finance, revenue, and more. The release also delivers enhancements for data engineers, data scientists, and developers that optimize their experience in Aera Developer™, the platform’s integrated development environment (IDE) for creating and deploying Skills, or modifying any deployed Aera Cognitive Skills.
Product release highlights:
-
Enhancements to Aera Cortex™, the data science engine inside the Aera Cognitive Operating System™, to improve the user experience, including:
- New Aera Notebook: Jupyter Notebook open interface provides the ideal environment to easily integrate data science projects and other custom code using Python and R, into Decision Intelligence flows, right from the Aera Decision Cloud platform.
- New AutoML: Machine learning options enable development of ML decision models — without requiring expertise in model creation, tuning, and deployment.
- New Model Performance and Versioning: New enhancements automate monitoring, deployment, and versioning of machine learning models to make it much easier to operationalize ML models and scale across the entire enterprise.
-
Advanced intelligence capabilities to provide a deeper understanding of relationships and effectiveness of decisions, including:
- New Graph Explorer: Advanced graph capabilities to enable data relationships to be used effectively in the decision-making process.
- New Confidence Score: Confidence score framework, which learns from past, similar recommendations and outcomes, helps determine the decisions that can be automated.
- New Action Item Node: Addition of a node within the Aera Developer environment to simplify decision management through the ability to more easily create, update, close, and access recommendations.
“Through Aera Decision Cloud, we are re-inventing decision making and accelerating adoption of Decision Intelligence,” said Shariq Mansoor, Founder and Chief Technology Officer, Aera Technology. "Today’s comprehensive release for both business end user and data science teams underscores how we are continually advancing and evolving our platform to enable digital decisions at scale in this increasingly complex business environment.”
To see a demo of Aera Decision Cloud and the new features, visit the Aera team at Booth #325, Gartner Supply Chain Symposium/Xpo™ 2022.
About the Gartner Supply Chain Symposium/Xpo™
Gartner Supply Chain Symposium/Xpo delivers the must-have insights, strategies and frameworks for CSCOs and supply chain leaders to drive impact within their organizations. Supply chain leaders will gather to gain a strategic view of the trends disrupting their business and the insights and frameworks they can use to prepare for disruption, enable digital transformation and build sustainability as a competitive advantage.
*Gartner, “ Predicts 2022: Data and Analytics Strategies Build Trust and Accelerate Decision Making,” Jorgen Heizenberg, Lydia Clougherty Jones, Ted Friedman, Andrew White, Saul Judah, Gareth Herschel, Rita Sallam, Ehtisham Zaidi, Svetlana Sicular, December 2021. https://www.gartner.com/document/4008991
GARTNER and SUPPLY CHAIN SYMPOSIUM/XPO ™ are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
About Aera Technology
Aera Technology is the Decision Intelligence company that makes business agility happen. The company’s innovative cloud platform integrates with existing systems to make and execute business decisions in real time. In the era of digital acceleration, Aera helps enterprises around the world transform how they respond to the ever-changing environment. For more information, visit www.aeratechnology.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005098/en/
Contact information
Zoe Kine
Zoe.kine@aeratechnology.com
Ph: 415-497-5285
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom